Last updated on February 2018

Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease


Brief description of study

Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

Detailed Study Description

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population.

Clinical Study Identifier: TX144012

Contact Investigators or Research Sites near you

Start Over

Jessica Fox

Renew Behavioral Health, Inc.
Long Beach, CA USA
  Connect »

Michelle Scott

Bradenton Research Center
Bradenton, FL USA
  Connect »

Charlene Carlo

The NeuroCognitive Institute
Mt. Arlington, NJ USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.